Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search
This leaflet answers some common questions about MonoFIX®-VF. It does not contain complete information about MonoFIX®-VF. It does not take the place of talking to your doctor. If you have any concerns about using this product, please talk to your doctor. Follow your doctor's advice, even if it is different from what this leaflet says.
Please read this leaflet carefully and keep it for future reference. However, the information in this leaflet is subject to change. Please check with your haemophilia treatment centre if there is any new information about this medicine that you should know since you were last treated with this medicine.
MonoFIX®-VF contains purified and concentrated factor IX, a protein which is essential for normal blood clotting. MonoFIX®-VF is used in patients with haemophilia B or Christmas disease, a bleeding disorder, in which there are reduced levels of the clotting factor. Also, it is available for use in surgery.
Individuals with factor IX levels lower than normal have difficulty in forming blood clots, with these clots often taking longer to be made than normal. Sometimes the individual may bleed unexpectedly into their joints, muscles or internal organs.
Ask your haemophilia treatment centre if you have any questions about why MonoFIX®-VF has been prescribed for you.
This product is made from human blood. When products are made from human blood and injected into you, it is possible that viruses or other substances could be present in the product and cause an illness. These could be viruses such as hepatitis, HIV , or parvovirus B19. There could also be other infectious agents some of which may not yet have been discovered.
To reduce the risk of this happening extra steps are taken when manufacturing this product. Strict controls are applied when selecting blood donors and donations. The product is specially treated to remove and kill viruses. This special treatment is considered effective against certain viruses known as enveloped viruses (such as HIV and hepatitis B and C), and also the non-enveloped virus, hepatitis A. The effect against the non-enveloped virus parvovirus B19 may be limited.
Vaccines are available against some of these viruses and your doctor will be able to help you decide whether it is worthwhile having any of those vaccines.
Please discuss the risks and benefits of this product with your doctor.
Should a break in the container or spillage occur, due precautions should be taken to avoid contamination of cuts and abrasions, as well as to avoid inhalation or swallowing of the spillage. Adequate disinfection can be obtained with the application of 1% sodium hypochlorite for 15 minutes. Commercial bleaches may be diluted appropriately as recommended to obtain this concentration.
Tell your doctor if you:
If you want further information, consult your doctor or haemophilia treatment centre.
The dosage and administration of MonoFIX®-VF must be carefully controlled. Your doctor will be responsible for determining what dose is appropriate to your condition.
MonoFIX®-VF will usually be given in a hospital. Should your doctor decide that treatment at home is appropriate, your haemophilia treatment centre will provide detailed instructions on how to use MonoFIX®-VF.
The following procedures are given as a guide only:
Allow the vial of MonoFIX®-VF and ampoule of Water for Injections 10 mL to reach room temperature prior to use, which may take one hour. Do not warm in hot water.
Equipment
The injection is best prepared by following each of the steps outlined in turn.
Note: Filter needles are intended to filter the contents of a single bottle of MonoFIX®-VF only.
If multiple bottles of MonoFIX®-VF are to be given a separate filter needle must be used for each bottle. However, one large syringe may be used to contain MMonoFIX®-VF.
Do not use the filter needle for injection.
Do not refrigerate MonoFIX®-VF once it has been prepared.
Use MonoFIX®-VF as soon as you can after preparation. The solution must not be stored and the infusion should be completed within 3 hours. This is important because bacteria could grow in the solution if it is left for longer periods and lead to infection in the blood. Any unused portion remaining in the vial must be discarded appropriately.
The injection is best given by following each of the steps outlined in turn.
Should any of the symptoms listed under "Unwanted effects" develop, stop the infusion immediately and contact your haemophilia treatment centre.
Along with their intended effects, medicines may cause some unwanted effects, which can sometimes be serious. Furthermore, individual patients may react differently to the same dose of the same medicine. This applies to MonoFIX®-VF. A constituent of this formulation (heparin) may lead to maternal bleeding episodes, thereby causing an increased incidence of foetal loss and prematurity.
Although severe reactions after MonoFIX®-VF injection are rare, high doses of factor IX may on rare occasions cause heart attacks, and blood clots. Ask your haemophilia treatment centre if you need more information.
Stop using this product immediately and contact your haemophilia treatment centre if any of the following side effects occur:
Contact your doctor immediately if you experience any of these symptoms at any time: fever, loss of appetite, extreme tiredness, abdominal pain, jaundice (yellow skin and eyes), dark urine, joint pains and skin rashes.
Overdosage may enhance the risk of heart attacks and blood clots. If you have questions, consult your haemophilia treatment centre.
Store at 2°C to 8°C (Refrigerate. Do not freeze). Protect from light. MonoFIX®-VF must not be used after the expiry date printed on the label.
This is not all the information that is available on MonoFIX®-VF. If you have any more questions or are not sure about anything, ask your haemophilia treatment centre.
MonoFIX®-VF is a white powder contained in a glass vial. The product comes with an ampoule of Water for Injection for reconstitution, and a special filter needle.
Each vial of MonoFIX®-VF contains 500 IU of factor IX. It also contains 100 IU of heparin sodium and 12.5 IU of antithrombin III. Other ingredients include human plasma proteins, sodium phosphate, sodium citrate and sodium chloride.
CSL (New Zealand) Limited
PO Box 62 590
Central Park
Auckland
NEW ZEALAND
CSL Limited ACN 051 588 348
at: 189-209 Camp Road
Broadmeadows 3047 VIC
AUSTRALIA
New Zealand Blood Service Limited
169 Manukau Road
Epsom
Auckland
NEW ZEALAND
This leaflet was prepared in July 1999.
® Registered trademark of CSL Limited.